News: Pharma

eNewsChannels NEWS: (IRVING, Texas) -- BioTE(R) Medical announces a forum of medical experts gathering before the Age Management Medicine Group (AMMG) to form consensus on testosterone therapy in women. The AMMG conference runs April 27-30, 2017 in Orlando, Florida.

eNewsChannels NEWS: (LAS VEGAS, Nev.) -- C Diff Foundation's 5th Annual International C.diff. Awareness Conference and Health EXPO will be hosted in Las Vegas, Nev. on November 9 & 10, 2017 at UNLV-Thomas and Mack Center. A panel of C. diff. survivors will join world-renowned experts delivering presentations on health care topics pertaining to the most common pathogen identified, a leading healthcare-associated infection (HAI) in U.S. hospitals alone: Clostridium difficile (C.diff.).

eNewsChannels NEWS: (CORTE MADERA, Calif.) -- Dr. Don Harte, chiropractic activist, says Trump's new panel, headed by Chris Christie, to deal with the opioid epidemic, is "philosophically and scientifically dead wrong." Dr. Harte declares, "The reason for this epidemic is clear. Orthopedists and other doctors freely prescribe Oxycontin, Fentanyl, Soma and other opioid drugs, get their patients addicted."

eNewsChannels NEWS: (AURORA, Colo.) -- Extreme Muscle Products (EMP) have announced the launch of its first formulation available for purchase, a product called Q-Meric. EMP is a newly created Colorado-based company focusing on health, wellness and athletic performance, with an emphasis on products that have synergistic effects.

eNewsChannels NEWS: (PORTLAND, Ore.,) -- Paragon BioTeck, Inc. announces a monumental ruling handed down by the United States Patent and Trademark Office (USPTO) affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies.

NEWS: (NEW YORK, N.Y.) National lawfirm Weitz and Luxenberg, P.C., said today it hopes potentially fatal side effects associated with SGLT2 inhibitor drugs will be reported to consumers faster, since people taking these next-generation diabetes medications deserve to be notified of the health dangers shortly after they have been reported to the U.S. Food and Drug Administration (FDA).

NEWS: Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, will sponsor a special reception during the J.P. Morgan 2016 Healthcare Conference, being held in San Francisco, Jan. 11-14. The conference, which is now in its 34th year, is an invitation-only event intended to create an environment of collaboration by bringing together stakeholders in the corporate, investor and financial sectors to learn about and explore market and sector trends.

NEWS: Weitz and Luxenberg, P.C., today announced that the firm has expanded the scope of its investigation into SGLT2 inhibitor drug injuries. SGLT2 inhibitor drugs include Invokana and others listed below. This move will allow the nationally known mass tort law and personal injury firm to focus on cases where people taking SGLT2 inhibitors were hospitalized after developing urosepsis (serious infection of the blood) or pyelonephritis (infection of the kidneys) from SGLT2 inhibitor-associated urinary tract infections.

NEWS: Philosys, Inc., the maker of Gmate(R) products, announced today that the U.S. Food and Drug Administration (FDA) has approved clearance for the Gmate SMART Blood Glucose Monitoring System and App for Android(TM). The Gmate SMART is a small, portable blood glucose meter that plugs into the headphone jack of a smartphone and provides fast and accurate blood glucose test results.

NEWS: Council for Vaccine Safety, and A Voice for Choice, in collaboration with community leaders, announce that on October 24, 2015 at 12 noon, protesters will rally at Frank Ogawa Plaza in Oakland, Calif. in solidarity with the Truth, Transparency and Freedom Rally happening on the same day at the CDC in Atlanta, Georgia.

NEWS: According to Harbor Compounding Pharmacy, many insurance plans are dropping coverage of compounded medications -- but some insurance plans still do cover for these custom formulations. Harbor Compounding Pharmacy provides resources and referrals to patients to find insurance coverage for their compounded medications during open enrollment 2016.

NEWS: Eularis announces the release of E-VAI, the latest development in sophisticated artificial intelligence (AI) technology delivering next generation analytics and decision making to Pharma marketers globally. E-VAI changes the game for marketers struggling to understand and get value from their marketing.

SAN PEDRO, Calif. /eNewsChannels/ -- NEWS: Schoenwetter Supplements, LLC announces the release of an advanced concept formulation of antioxidants, RxQ Antioxidant Complex. Its proprietary antioxidant formula takes into consideration not only adding antioxidants that can rapidly be depleted but is mindful of the necessary other constituents that serve to help recycle some important antioxidant systems that are everywhere present in our bodies.

ORLANDO, Fla. /eNewsChannels/ -- NEWS: BioTE Medical President and Founder Gary Donovitz M.D. releases his book 'Age Healthier Live Happier - Avoiding Over-Medication through Natural Hormone Balance' (ISBN: 9780990706458) to kick off the Age Management Medicine Group Conference at JW Marriott / Ritz Carlton Grande Lakes April 23-26, 2015.

NEW YORK, N.Y. /eNewsChannels/ -- NEWS: Ellen Relkin, of counsel attorney with Weitz and Luxenberg, P.C., has been named to the plaintiffs' steering committee created by judicial order to facilitate lawsuits against the makers of the anticoagulant drug Xarelto, the personal injury and mass tort law firm today announced.

PORTLAND, Ore. /eNewsChannels/ -- NEWS: Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announced today that it has received CE mark approval for the recently FDA cleared Comfortear Lacrisolve Absorbable Punctum Plug. CE mark approval is recognized and associated with safety and performance in multiple countries.

PORTLAND, Ore. /eNewsChannels/ -- NEWS: Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, will be exhibiting at the American Academy of Ophthalmology (Booth #4550) in Chicago on October 18-21, 2014.

PLYMOUTH, Minn. /eNewsChannels/ -- NEWS: SilkTears, LLC, a privately held, research-based and product-driven biotechnology company, announced today that advances in protein-based excipient technology may allow for the development of artificial tear products that will more closely represent certain characteristics of the natural makeup of the tear film, and may help the significant population of patients suffering from dry eye syndrome.

CLEVELAND, Ohio /eNewsChannels/ -- NEWS: Ohio's Lakewood College today announced a new payment plan option that will allow students to graduate from the Pharmacy Technician Certificate Program without going thousands of dollars into debt. Lakewood College is committed to helping students achieve their goals affordably.

PORTLAND, Ore. /eNewsChannels/ -- NEWS: Paragon BioTeck, Inc., a privately held U.S. biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, announces its FDA approved Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil, is readily available through Bausch + Lomb.

NEW YORK CITY, N.Y. /eNewsChannels/ -- NEWS: Actos manufacturer Takeda and its partner Eli Lilly were hit this week with a $9 Billion verdict over the safety of their popular diabetes drug. After a two month trial, the jury found that Weitz and Luxenberg client Terrence Allen's use of Actos caused bladder cancer and the drug manufacturer and marketer failed to warn of this life-threatening risk.

PORTLAND, Ore. /eNewsChannels/ -- NEWS: Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, received FDA approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil on March 21, 2013.

HUNTINGTON BEACH, Calif. /eNewsChannels/ -- NEWS: SignatureCLL today announced that the first laboratory test ever shown in a clinical trial to improve one year survival rates in cancer is now available to patients with chronic lymphocytic leukemia (CLL). The U.S. cancer physician who invented the test and the British scientist who used it to make discoveries in leukemia will offer the test under the trade name SignatuRx through their own, newly-formed laboratory company.

PORTLAND, Ore. /eNewsChannels/ -- NEWS: Biopharmaceutical company Paragon BioTeck, Inc. today announced that it plans to launch its new line of products, known as Ilast(R), at the Annual American Academy of Ophthalmology meeting in New Orleans. Paragon signed an exclusive distribution agreement with Horus Pharma to supply Ilast(R) ocular care products in the U.S. last month, and the company is excited to release these products to ophthalmology professionals.

CHICAGO, Ill. /eNewsChannels/ -- NEWS: Nutronics Labs, a Natural supplement company, today released a statement encouraging deer antler spray consumers to do thorough product research before buying health supplements online. Nutronics Labs is the leading manufacturer of deer antler spray and boasts the world's strongest supplements available.